igen biotech


igen biotech is working on development of a diversified portfolio of short, medium and long-term products. Our current portfolio is composed of the following projects:

EPiGEN kit project (2015-2019): "Development and clinical validation of a CE-IVD kit, based on epigenetic biomarkers, capable of personalizing treatment in non-small cell lung cancer in advances stages".

igen biotech collaborates with the University Hospital of La Paz (Madrid), and the Fundación Ramón Domínguez of the Hospital of Santiago de Compostela, to validate the EPiGEN kit. With 1.647.885,18  total budget, the project is supported by the Spanish Ministry of Economy, Industry and Competitiveness through the Retos-Colaboración 2015 and 2016 programs, and counts on two seals of excellence bestowed by the European Commission under Phase 2 of the SME instrument of H2020 program. 

cfDNA liquid biopsy project (2017-2019): "Development and validation of a CE-IVD circulating cell-free DNA extraction kit from liquid biopsy samples". 

Based on its own tecnology, igen biotech is working in the development of a kit for circulating cell free DNA from plasma/serum samples (liquid biopsy) with application in Non Invasive Prenatal Diagnosis or Biomarkers Analysis in several fields of medicine (personalizing medicine). 

EIMMI project (2015-2019): "Development and validation of a system of genetic and/or epigenetic biomarkers to personalize treatment of autoimmune and inflammatory diseases". 

With 517.736,70  total budget and supported by the Spanish Ministry of Economy, Industry and Competitiveness through the Retos-Colaboración 2015 program, this collaborative project is carried out by the consortium: igen biotech, Fundación de Investigación del Hospital Universitario de la Princesa, Universidad Complutense de Madrid, Making Genetics, ilab tech and Anàlisis Mèdiques Barcelona. 

Other Projects

Additionally, igen biotech participated in several collaborative projects in the past:

Apta4 project (2011-2015): The Apta4 project results from the framework agreement established between igen and the Hospital Ramón y Cajal (Madrid) for joint development of a technology platform for selection of aptamers, able to recognize certain therapeutic targets with high affinity and specificity.

Led by igen biotech and formed by four companies and two reseach centers (a university and a hospital), the aim of the Apta4 was to develop and validate a kit for evaluation of intestinal absortive mass for diagnostic porpuses, based on APOAIV protein-selective aptamers technology. The project started in 2011 and was cofunded by the Spanish Ministry of Economy (MINECO), by the INNPACTO program.  

ivagintest project (2012-2016): Led by igen biotech, in collaboration with a university and a technological center, the goal of this project was to develop a multi-diagnosis POC (point-of-care) kit for gynecological diseases. The project started in 2012 and was also co-funded by the Spanish Ministry of Economy (MINECO), within the INNPACTO program. 

Gene-Frail project (2011-2017): This is a sub-study part of the FP7 project MID-FRAIL STUDY, supported by the European Commision through its 7th Framework Programme. Its aim was to develop a test based on the polymorphisms of three genes (Pro259Arg-TCN2 gene; ACE I/D-ACE gene and e2/e3/e4-ApoE gene) to stablish their predictive value for the development of disability and response to treatment. The project involves the analysis of more than 400 blood samples from volunteers by a prospective and interventional study with a number of European hospitals participating. The project started in 2011 and lasted until 2017. 



C/ Gustavo Fernandez Balbuena nº 11      28002 MADRID (SPAIN)     t: +34 91 510 29 99      f: +34 91 519 13 26      igen@igenbiotech.com      

Diseñado por sitelicon.com